New bacterial therapy approach to treat lung cancer


New bacterial therapy approach to treat lung cancer

Fluorescence microscopy image of lung cancer cells stained with antibodies against proteins involved in cell growth. Credit: Dhruba Deb/Columbia Engineering

Lung cancer is the deadliest cancer in the United States and around the world. Many of the currently available therapies have been ineffective, leaving patients with very few options. A promising new strategy for treating cancer has been bacterial therapy, but although this treatment modality has rapidly progressed from laboratory experiments to clinical trials over the last five years, the most effective treatment for certain types of cancer may be a combination with other drugs.

Columbia Engineering researchers report that they have developed a preclinical evaluation pipeline for characterizing bacterial therapies in lung cancer models. Their new study, published on December 13, 2022, by Scientific Reports, combines bacterial therapies with other treatment modalities to improve treatment efficacy without any additional toxicity. This new approach was able to rapidly characterize bacterial therapies and successfully integrate them into current targeted lung cancer therapies.

“We anticipate a rapid and selective expansion of our pipeline to improve the efficacy and safety of treatment for solid tumours,” said first author Dhruba Deb, associate research scientist studying the effect of bacterial toxins on lung cancer in Professor Tal’s laboratory. Danino in Biomedical Engineering. , “As someone who has lost loved ones to cancer, I would like to see this strategy move from the bench to the bedside in the future.”

The team used RNA sequencing to find out how cancer cells were responding to bacteria at the cellular and molecular levels. They hypothesized that molecular pathways in cancer cells were helping the cells to be resistant to bacterial therapy. To test their hypothesis, the researchers blocked these pathways with current cancer drugs and showed that combining the drugs with bacterial toxins is more effective in eliminating lung cancer cells. They validated the combination of bacterial therapy with an AKT inhibitor as an example in lung cancer mouse models.

“This new study describes an exciting pipeline of drug development that was previously untapped in lung cancer – the use of bacteria-derived toxins,” said Upal Basu Roy, Executive Director of Research, LUNGevity Foundation, USA. “The preclinical data presented in the manuscript provide a strong rationale for further research in this area, thereby opening up the possibility of new treatment options for patients diagnosed with this deadly disease.”

Deb plans to expand her strategy into larger studies in preclinical models of difficult-to-treat lung cancers and collaborate with clinicians to drive clinical translation.

More information:
Dhruba Deb et al, Combination therapy design for engineered bacterial therapy in non-small cell lung cancer, Scientific Reports (2022). DOI: 10.1038/s41598-022-26105-1

Provided by Columbia University School of Engineering and Applied Science

Quote: New Bacterial Therapy Approach to Treating Lung Cancer (2022, Dec 24) retrieved Dec 25, 2022 from .html

This document is subject to copyright. Apart from all fair dealing for purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.